FL115
- Generic Name
- FL115
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Suzhou Forlong Biotechnology Co.,Ltd,
- Target Recruit Count
- 18
- Registration Number
- NCT06130722
- Locations
- 🇺🇸
Moores Cancer Center at UCSD Health, San Diego, California, United States
🇺🇸HOAG Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Gabriel Cancer Center, Canton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath